Human Tumor Stem Cell Drug Sensitivity Assays

Human tumor stem cell drug sensitivity assays, including applications using tumor microorgans, are considered experimental and are not covered by Medicare. The assays' intended use to predict individual patient tumor responses and guide drug selection is therefore not a covered indication.

"Human tumor drug sensitivity assays are considered experimental and are not covered by Medicare."

Sign up to see full coverage criteria, indications, and limitations.